Back to Journals » OncoTargets and Therapy » Volume 9
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
10,202 | Dovepress* | 9,240+ | 1,370 | 10,610 | |
PubMed Central* | 962 | 328 | 1,290 | ||
Totals | 10,202 | 1,698 | 11,900 | ||
*Since 10 May 2016 +Since July 2016 |
View citations on PubMed Central and Google Scholar